{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T15:19:13Z","timestamp":1781450353717,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070330"],"award-info":[{"award-number":["82070330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejphar.2022.175357","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T18:28:54Z","timestamp":1666981734000},"page":"175357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction"],"prefix":"10.1016","volume":"936","author":[{"given":"Yang","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175357_bib1","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s11010-022-04411-6","article-title":"Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression","volume":"477","author":"Abdulrahman","year":"2022","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2022.175357_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119440","article-title":"Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia","volume":"276","author":"Azam","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2022.175357_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2022.175357_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-020-01208-z","article-title":"Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF","volume":"20","author":"Bode","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2022.175357_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.ejphar.2022.175357_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","article-title":"Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction","volume":"17","author":"Connelly","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2022.175357_bib7","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2022.175357_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173614","article-title":"Chronic sigma-1 receptor activation ameliorates ventricular remodeling and decreases susceptibility to ventricular arrhythmias after myocardial infarction in rats","volume":"889","author":"Fo","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175357_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCRESAHA.118.312017","article-title":"Metabolic coordination of physiological and pathological cardiac remodeling","volume":"123","author":"Gibb","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2022.175357_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115437","article-title":"Low-dose empagliflozin improves systolic heart function after myocardial infarction in rats: regulation of MMP9, NHE1, and SERCA2a","volume":"22","author":"Goerg","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175357_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2022.175357_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein & cell"},{"key":"10.1016\/j.ejphar.2022.175357_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejphar.2018.11.025","article-title":"Loss of MD1 exacerbates myocardial ischemia\/reperfusion injury and susceptibility to ventricular arrhythmia","volume":"844","author":"Jiang","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175357_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030866","article-title":"Role of non-myocyte gap junctions and connexin hemichannels in cardiovascular Health and disease: novel therapeutic targets?","volume":"19","author":"Johnson","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2022.175357_bib15","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/CIRCRESAHA.108.190454","article-title":"Structural and molecular mechanisms of gap junction remodeling in epicardial border zone myocytes following myocardial infarction","volume":"104","author":"Kieken","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2022.175357_bib16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","article-title":"Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury","volume":"19","author":"Lahnwong","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2022.175357_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/01.CIR.101.5.547","article-title":"Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice","volume":"101","author":"Lerner","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2022.175357_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106049","article-title":"Sodium glucose cotransporter 1 (SGLT1) inhibitors in cardiovascular protection: mechanism progresses and challenges","volume":"176","author":"Li","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejphar.2022.175357_bib19","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2022.175357_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147836","article-title":"Inhibition of the unfolded protein response reduces arrhythmia risk after myocardial infarction","volume":"131","author":"Liu","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2022.175357_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105788","article-title":"Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice","volume":"161","author":"Liu","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci. : official journal of the European Federation for Pharmaceutical Sciences"},{"key":"10.1016\/j.ejphar.2022.175357_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165807","article-title":"Empagliflozin improves left ventricular diastolic function of db\/db mice","volume":"1866","author":"Moellmann","year":"2020","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2022.175357_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1152\/physrev.00014.2006","article-title":"Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation","volume":"87","author":"Nattel","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2022.175357_bib24","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/j.2040-4603.2017.tb00771.x","article-title":"Cardiac fibrosis and arrhythmogenesis","volume":"7","author":"Nguyen","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejphar.2022.175357_bib25","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2022.175357_bib26","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1038\/s41598-017-05379-w","article-title":"Loss of MD1 exacerbates pressure overload-induced left ventricular structural and electrical remodelling","volume":"7","author":"Peng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175357_bib27","doi-asserted-by":"crossref","first-page":"5116","DOI":"10.1038\/s41598-017-05379-w","article-title":"Loss of MD1 exacerbates pressure overload-induced left ventricular structural and electrical remodelling","volume":"7","author":"Peng","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175357_bib28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","article-title":"Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction","volume":"110","author":"Perrier","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2022.175357_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0008-6363(99)00013-9","article-title":"Electrical remodeling in ischemia and infarction","volume":"42","author":"Pinto","year":"1999","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2022.175357_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-020-01040-5","article-title":"Empagliflozin prevents doxorubicin-induced myocardial dysfunction","volume":"19","author":"Sabatino","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejphar.2022.175357_bib31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jphs.2019.11.001","article-title":"Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice","volume":"142","author":"Sawa","year":"2020","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2022.175357_bib32","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1177\/0148607104028005364","article-title":"The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function","volume":"28","author":"Scheepers","year":"2004","journal-title":"JPEN - J. Parenter. Enter. Nutr."},{"key":"10.1016\/j.ejphar.2022.175357_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3920195","article-title":"A review of the molecular mechanisms underlying the development and progression of cardiac remodeling","volume":"2017","author":"Schirone","year":"2017","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejphar.2022.175357_bib34","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/17512433.2021.1908123","article-title":"Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial","volume":"14","author":"Shah","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175357_bib35","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.numecd.2019.06.004","article-title":"Loss of MD1 increases vulnerability to ventricular arrhythmia in diet-induced obesity mice via enhanced activation of the TLR4\/MyD88\/CaMKII signaling pathway","volume":"29","author":"Shuai","year":"2019","journal-title":"Nutr. Metabol. Cardiovasc. Dis. : Nutr. Metabol. Cardiovasc. Dis."},{"key":"10.1016\/j.ejphar.2022.175357_bib36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1161\/CIRCULATIONAHA.120.051517","article-title":"Targeting 5-HT2B receptor signaling prevents border zone expansion and improves microstructural remodeling after myocardial infarction","volume":"143","author":"Snider","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2022.175357_bib37","article-title":"CaMKII and GLUT1 in heart failure and the role of gliflozins. Biochimica et biophysica acta","volume":"1866","author":"Trum","year":"2020","journal-title":"Mol. Basis Dis."},{"key":"10.1016\/j.ejphar.2022.175357_bib38","first-page":"712","article-title":"Traditional and novel electrocardiographic conduction and repolarization markers of sudden cardiac death","volume":"19","author":"Tse","year":"2017","journal-title":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology"},{"key":"10.1016\/j.ejphar.2022.175357_bib39","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2022.175357_bib40","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3389\/fphar.2020.00993","article-title":"Shensong Yangxin protects against metabolic syndrome-induced ventricular arrhythmias by inhibiting electrical remodeling","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175357_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.738594","article-title":"Sotagliflozin, a dual SGLT1\/2 inhibitor, improves cardiac outcomes in a normoglycemic mouse model of cardiac pressure overload","volume":"12","author":"Young","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2022.175357_bib42","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur. J. Heart Fail."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922006185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922006185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:08:26Z","timestamp":1757977706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922006185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":42,"alternative-id":["S0014299922006185"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175357","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of sotagliflozin on ventricular arrhythmias in mice with myocardial infraction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175357"}}